The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Table 6

Results of cost-effectiveness analysis.

		Denosumab	Alternative	Difference	ICER (€/QALY)
Risedronate	Total costs	22,399	21,819	579	10,302
	QALYs	10.46	10.40	0.06
Generic alendronate	Total costs	22,399	21,621	778	18,047
	QALYs	10.46	10.41	0.04
Branded alendronate	Total costs	22,399	21,661	738	17,133
	QALYs	10.46	10.41	0.04
Ibandronate	Total costs	22,399	22,238	161	2,158
	QALYs	10.46	10.38	0.07
Strontium ranelate	Total costs	22,399	22,394	5	69
	QALYs	10.46	10.39	0.07